<DOC>
	<DOCNO>NCT00122382</DOCNO>
	<brief_summary>This world wide study evaluate remission joint damage subject treat abatacept addition methotrexate versus subject receive methotrexate along placebo .</brief_summary>
	<brief_title>Remission Joint Damage Progression Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis ( RA ) &lt; =2 year ; MTX naive &lt; =10 mg/wk &lt; =3 week . No dose within 3 month prior inform consent . CReactive Protein ( CRP ) &gt; = 4.5 mg/L ( amendment ) Rheumatoid factor anticyclic citrullinated peptide antibody ( antiCCP ) positive Tender joint &gt; =12 swollen joint &gt; =10 Women men willing use birth control Diagnosed rheumatic disease History cancer within 5 year Active tuberculosis Treatment another investigation drug within 28 day Active bacterial viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>abatacept , methotrexate , erosive RA</keyword>
</DOC>